Biodexa Pharmaceuticals Management

Management criteria checks 4/4

Biodexa Pharmaceuticals' CEO is Stephen Stamp, appointed in Sep 2019, has a tenure of 4.08 years. total yearly compensation is £237.90K, comprised of 99.4% salary and 0.6% bonuses, including company stock and options. directly owns 0.001% of the company’s shares, worth €21.88. The average tenure of the management team and the board of directors is 2.8 years and 6.5 years respectively.

Key information

Stephen Stamp

Chief executive officer

UK£237.9k

Total compensation

CEO salary percentage	99.4%
CEO tenure	4.1yrs
CEO ownership	0.0007%
Management average tenure	2.8yrs
Board average tenure	6.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Stephen Stamp's remuneration changed compared to Biodexa Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2023	n/a	n/a	-UK£8m
Mar 31 2023	n/a	n/a	-UK£8m
Dec 31 2022	UK£238k	UK£236k	-UK£8m
Sep 30 2022	n/a	n/a	-UK£7m
Jun 30 2022	n/a	n/a	-UK£5m
Mar 31 2022	n/a	n/a	-UK£5m
Dec 31 2021	UK£329k	UK£187k	-UK£5m
Sep 30 2021	n/a	n/a	-UK£7m
Jun 30 2021	n/a	n/a	-UK£8m
Mar 31 2021	n/a	n/a	-UK£15m
Dec 31 2020	UK£193k	UK£175k	-UK£22m
Jun 30 2020	n/a	n/a	-UK£22m
Mar 31 2020	n/a	n/a	-UK£16m
Dec 31 2019	UK£207k	UK£50k	-UK£9m

Compensation vs Market: Stephen's total compensation ($USD288.33K) is below average for companies of similar size in the German market ($USD418.12K).

Compensation vs Earnings: Stephen's compensation has been consistent with company performance over the past year.

CEO

Stephen Stamp (61 yo)

4.1yrs

Tenure

UK£237,897

Compensation

Mr. Stephen A. Stamp serves as Chief Financial Officer and Director of Biodexa Pharmaceuticals Plc (formerly known as Midatech Pharma plc) since September 9, 2019. He serves as Chief Executive Officer at B...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Stephen Stamp	CEO, CFO	4.1yrs	UK£237.90k	0.00066% € 21.9
Dmitry Zamoryakhin	Chief Scientific Officer	2.3yrs	UK£236.68k	0% € 0
Daniel Palmer	Vice President of Technology	2.8yrs	no data	no data
Fiona Sharp	Group Financial Controller	no data	no data	no data

2.8yrs

Average Tenure

Experienced Management: 5MP0's management team is considered experienced (2.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Stephen Stamp	CEO, CFO	4.1yrs	UK£237.90k	0.00066% € 21.9
Simon Turton	Senior Independent Non-Executive Director	8.8yrs	UK£31.54k	0.00066% € 21.9
Stephen Parker	Independent Non-Executive Chairman	1.3yrs	UK£43.84k	no data
Daniel McCurdy	Member of Scientific Advisory Board	no data	no data	no data
Sijmen de Vries	Independent Non-Executive Director	19yrs	UK£31.54k	0.00033% € 10.9
Michael Natan	Member of Scientific Advisory Board	no data	no data	no data
Francesco Stellaci	Chairman of Scientific Advisory Board	no data	no data	no data
David Male	Member of Scientific Advisory Board	no data	no data	no data
Lorraine O'Driscoll	Member of Scientific Advisory Board	no data	no data	no data
Soledad Penades	Member of Scientific Advisory Board	no data	no data	no data
Jean-Christophe Roux	Member of Scientific Advisory Board	no data	no data	no data
Silke Krol	Member of Scientific Advisory Board	no data	no data	no data

6.5yrs

Average Tenure

64yo

Average Age

Experienced Board: 5MP0's board of directors are considered experienced (6.5 years average tenure).

Biodexa Pharmaceuticals Management

Management criteria checks 4/4

Key information

Recent management updates

Biodexa Pharmaceuticals Plc, Annual General Meeting, Jun 13, 2024

Biodexa Appoints Ann Merchant to the Board of Directors

Recent updates

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadlier Brain Cancer

Biodexa Announces Successful Appeal of Nasdaq Delisting

Biodexa Pharmaceuticals PLC Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma

Biodexa Pharmaceuticals plc Announces to Made the Final Match Payment with Respect to A $17 Million Grant from the Cancer Prevention Research Institute of Texas

Biodexa Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination - Plans to Appeal

Biodexa Pharmaceuticals Plc has completed a Follow-on Equity Offering in the amount of $5.009969 million.

Biodexa Pharmaceuticals Plc has completed a Follow-on Equity Offering in the amount of $5.009968 million.

Biodexa Pharmaceuticals Plc Announces Additional Positive Results of Phase 2 Trial of eRapa in Treatment of Precancerous Polyps in the GI Tract - Now 12-Month Data

Biodexa Pharmaceuticals PLC Announces Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024

Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ At 12 Months in Familial Adenomatous Polyposis (Fap)

Biodexa Pharmaceuticals plc Announces Promising Phase 2 Results for Its Newly In-Liced Drug Erapa for Treating Fam Fam Famic Adenomatous Polyposis

Biodexa Pharmaceuticals PLC Announces Positive Statistically Significant Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting

Biodexa Pharmaceuticals Plc, Annual General Meeting, Jun 13, 2024

Biodexa Pharmaceuticals Plc's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers

Biodexa Pharmaceuticals plc Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update

Biodexa Pharmaceuticals plc Reports 12 Month Survival in Magic-G1 Study of Mtx110 in Recurrent Glioblastoma Patients

Biodexa Appoints Ann Merchant to the Board of Directors

Biodexa Pharmaceuticals Plc has completed a Composite Units Offering in the amount of $5.217389 million.

Biodexa Pharmaceuticals plc Completes Recruitment of Cohort A in Study of Mtx110 in Patients with Recurrent Glioblastoma

Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of Mtx-110 (Magic-G1 Study) in Patients with Recurrent Glioblastoma At 2023 Annual European Association of Neuro-Oncology Meeting (Eano)

Biodexa Regain Compliance with Nasdaq Minimum Bid Price Requirement

Biodexa Ltd Announces Completion of Enrolment and Treatment in the Phase 1 Study of Mtx110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (Dmgs)

Biodexa Pharmaceuticals Announces Results of Appeal of Delisting Determination

Biodexa Pharmaceuticals plc Announces the Publication of the Results of an Investigator-Initiated Phase I Study Pnoc015

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age